Leuko, an MIT spin-out, is developing the world?s first non-invasive white blood cell (WBC) monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible – it requires patient travel, blood draws and laboratory infrastructure. This currently limits the frequency of monitoring, which puts patients? health, and even lives, at risk. Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device. Leuko?s vision is to empower patients and their loved ones, and make their lives better and safer by providing them with broad and immediate access to non-invasive blood testing.